A5103120025- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension Research and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Medical Imaging and Pathology Studies
- Neonatal Respiratory Health Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Systemic Sclerosis and Related Diseases
- Occupational and environmental lung diseases
- Inhalation and Respiratory Drug Delivery
- Occupational exposure and asthma
- Eosinophilic Disorders and Syndromes
- Respiratory and Cough-Related Research
- Pleural and Pulmonary Diseases
- Congenital Diaphragmatic Hernia Studies
- Tissue Engineering and Regenerative Medicine
- Respiratory Support and Mechanisms
- Lung Cancer Treatments and Mutations
- Asthma and respiratory diseases
- Heat shock proteins research
- Connective Tissue Growth Factor Research
- Pneumonia and Respiratory Infections
- Inflammatory Myopathies and Dermatomyositis
- Head and Neck Cancer Studies
- Respiratory viral infections research
- Chronic Myeloid Leukemia Treatments
McMaster University
2016-2025
Vancouver General Hospital
2025
St. Joseph’s Healthcare Hamilton
2016-2025
University of Calgary
2025
University of British Columbia
2021-2025
University of Toronto
2021-2025
St. Paul's Hospital
2025
St. Paul's Hospital
2025
Université de Montréal
2025
St Joseph's Health Care
2016-2024
Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients idiopathic pulmonary fibrosis.We conducted two replicate 52-week, randomized, double-blind, 3 trials (INPULSIS-1 INPULSIS-2) to evaluate the efficacy safety compared placebo fibrosis. The primary end point was annual rate forced vital capacity...
Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression lung fibrosis. Although efficacy nintedanib has been shown idiopathic pulmonary fibrosis, its across a broad range fibrosing diseases is unknown.
IL-1β is one of a family proinflammatory cytokines thought to be involved in many acute and chronic diseases. Although it considered participate wound repair, no major role has been attributed tissue fibrosis. We used adenoviral gene transfer transiently overexpress rat lungs after intratracheal administration. The high expression the first week injection was accompanied by local increase IL-6 TNF-α vigorous inflammatory response with evidence injury. profibrotic PDGF TGF-β1 were increased...
Key Principle #1: Causal inference requires careful consideration of confounding d Preferred variable selection methods 1. Historical confounder definition with purposeful 2. models using directed acyclic graphs Variable that do not adequately control for 3. P value-or model-based 4. Methods based on b-coefficient changes 5. Selection variables to identify "independent predictors" Do present all the effect estimates from a model designed test single causal association (Table 2 fallacy) #2:...
The clinical management of idiopathic pulmonary fibrosis (IPF) remains a major challenge due to lack effective drug therapy or accurate indicators for disease progression. Fibrocytes are circulating mesenchymal cell progenitors that involved in tissue repair and fibrosis.To test the hypothesis assay these cells may provide biomarker activity progression IPF.Fibrocytes were defined as positive CD45 collagen-1 by flow cytometry quantified patients with stable IPF during acute exacerbation...
Abstract Transforming growth factor-β1 plays a key role in the pathogenesis of pulmonary fibrosis, mediating extracellular matrix (ECM) gene expression through series intracellular signaling molecules, including Smad2 and Smad3. We show that Smad3 null mice (knockout (KO)) develop progressive age-related increases size alveolar spaces, associated with high spontaneous presence metalloproteinases (MMP-9 MMP-12) lung. Moreover, transient overexpression active TGF-β1 lungs, using adenoviral...
Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few these replicated beneficial effects clinical trials. Given the challenges associated with performing trials patients idiopathic (IPF), it is imperative that preclinical data packages be robust their analyses and interpretations to best chance selecting promising drug candidates advance The American Thoracic Society has convened a group experts lung discuss formalize...
Introduction Comorbidities significantly influence the clinical course of idiopathic pulmonary fibrosis (IPF). However, their prognostic impact is not fully understood. We therefore aimed to determine comorbidities, as individual and whole, on survival in IPF. Methods The database a tertiary referral centre for interstitial lung diseases was reviewed treatments, frequency IPF patients. Results 272 patients were identified which 12% had no, 58% 1–3 30% 4–7 mainly cardiovascular, oncologic...
Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is now among the most frequently used antiretroviral agents. However, recent reports have raised concerns about potential neurotoxicity.We performed retrospective analysis of cohort HIV-infected patients who had initiated an INSTI in two large German out-patient clinics between 2007 and 2016. We compared discontinuation rates because adverse events (AEs) within 2 years starting treatment with dolutegravir,...
Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusion capacity lungs carbon monoxide (DlCO), symptoms, and quality life in patients with IPF severely decreased DlCO. That idea was tested this trial.We randomly assigned, 1:1 ratio, DlCO 35% or less predicted value to receive nintedanib at dose 150 mg twice...
<h3>Rationale</h3> There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not treat patients with preserved lung volume. <h3>Objective</h3> To investigate whether IPF and volume receive the same benefit from nintedanib more impaired <h3>Methods</h3> Post hoc subgroup analyses of pooled data two replicate phase III INPULSIS trials by baseline FVC % predicted (≤90%, >90%). <h3>Results</h3> At baseline, 274 had >90%...
Rationale: Recent findings suggesting transforming growth factor (TGF)-β1 activation by mechanical stimuli in vitro raised the question of whether this phenomenon was relevant vivo context pulmonary fibrosis.Objectives: To explore effect stress on TGF-β1 and its signaling pathway rat human fibrotic lung tissue using a novel ex model.Methods: Rat fibrosis induced transient gene expression active TGF-β1. Lungs were harvested at Day 14 or 21 submitted to various bath equipped with force...
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterised by worsening respiratory symptoms and physiological impairment. Increasing awareness of the clinical manifestations IPF, more widespread use computed tomography scans other potential factors have contributed to rising prevalence IPF over last two decades, especially among people age 65 years. Significant advances in understanding pathobiology emerged, multiple genetic nongenetic contributors been...